Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan

NCT03147677 is registered in ClinicalTrials.gov with The Third Xiangya Hospital of Central South University as lead sponsor.

NCT NCT03147677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03147677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan
Lead sponsor
The Third Xiangya Hospital of Central South University
Phase
Phase 4
Overall status
Completed
Start date
July 28, 2016
Completion date
December 30, 2018
Enrollment
60 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetic nephropathy